Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $846,215.37 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,999 shares of the stock in a transaction on Monday, July 13th. The stock was sold at an average price of $84.63, for a total transaction of $846,215.37. Following the transaction, the senior vice president directly owned 15,312 shares in the company, valued at approximately $1,295,854.56. This represents a 39.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total transaction of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $86.65 on Thursday. Oruka Therapeutics, Inc. has a one year low of $12.84 and a one year high of $97.78. The company has a market cap of $5.23 billion, a PE ratio of -44.66 and a beta of -0.35. The stock has a 50-day moving average of $71.57 and a 200-day moving average of $52.65.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. Analysts expect that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Oruka Therapeutics

Large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new position in Oruka Therapeutics during the 1st quarter worth $2,505,000. JPMorgan Chase & Co. raised its holdings in shares of Oruka Therapeutics by 567.7% in the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after purchasing an additional 13,115 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics during the second quarter valued at about $28,000. Rhumbline Advisers bought a new position in shares of Oruka Therapeutics during the second quarter valued at about $320,000. Finally, New York State Common Retirement Fund purchased a new position in Oruka Therapeutics during the second quarter worth about $96,000. 56.44% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ORKA has been the topic of a number of recent research reports. Wedbush set a $165.00 target price on Oruka Therapeutics in a report on Monday, April 27th. HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 23rd. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. UBS Group raised their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Finally, BTIG Research reiterated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Monday. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.